1.
Pediatr Infect Dis J
; 32(10): 1144-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23584584
RESUMO
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus infection in infants. The potential for palivizumab to interfere with commercially available respiratory syncytial virus diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.